Patients with pulmonary arterial hypertension and cardiovascular comorbidities may benefit from the use of inhaled or oral ...

Living with Pulmonary Arterial Hypertension (PAH) affects not only patients but also the caregivers who support them, facing ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

StockNews.com lowered shares of United Therapeutics (NASDAQ:UTHR – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning. Other equities ...

MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for ...

Innovative health and medical research that supports commercialisation as it progresses from proof of concept through to clinical implementation will ...

Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of ...

Merck’s Winrevair (sotatercept) for PAH Winrevair was greenlit March 26 for treating adults ... which notched an FDA approval March 14 as the first treatment for the liver disease in patients with ...

People with pulmonary arterial hypertension and their physicians hardly ever agree on the severity of symptoms, a study shows ...

Pulmonary arterial hypertension (PAH) is a disorder that is typically characterized by symptoms such as exertional dyspnea and a reduction in exercise capacity. These disease manifestations have a ...

Using in-depth analyses and machine learning, researchers identified metabolic molecules and genes that may be diagnostic ...

Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, the University of Kiel, and the Leibniz Institute of ...